Good news frequently arrives | γ• Haibu Pharmaceutical has✘δ been awarded the 2023 Star'≤'↕ Council Member Unit b$↔y the National Federation of In£βΩdustry and Commerce Pharmaceutica ≈l Industry Chamber.

On April 15, 2024, the 2nd Council Meet≥πing of the 4th Session of t↓Ω÷he All-China Federatiδ&δon of Industry and Commerce Ph♣★armaceutical Industry C §§hamber of Commerce and the Pharmac>&&eutical Industry Development F™φ orum in the Xihongqiao Business Distric☆¶$t were held in the Xihongqiao Busines&α☆‌s District with the theme ↕₽"Gathering Strength for Pharmaceu≠βtical Innovation, Advancing✔Ω Industry Towards Ne×€¥↑w Directions." The council♣∑ meeting is an annual routine  →meeting of the chambe< ≥r, attended by over 400 represφ₩entatives from various c←$​ouncils.

At the themed dinner, award<®↔s were presented for star-level vice pΩ∞residents, star-level executive ₹✘€directors, star-level directors, a↓•'nd star-level members a↕¶↓¥pproved by the council. Haibu Ph± armaceutical was awarded as a "Star-Lev€"'∑el Director Unit of t☆∑αhe National Federation of Industry ≠∏¶§and Commerce Pharmaceutica↓↕αl Industry Chamber of Commer®®ce 2023."

China National Federation ε>δof Industry and Commerce Pharmaceutic∏✔>al Industry Chamber of Comε↔>γmerce(Abbreviated as: National F< ∏ederation of Industry and Com$↑merce Pharmaceutical Industry Chamb​€©er), approved by Document No. 200613 fΩ䶧rom the All-China Federation o✔¶✘αf Industry and Commerc≈δ♦↑e, officially established on July 25, 2φβ©≠006, at the Great Hall of the Peop∑β®©le in Beijing. The cha∞♠mber is a national industry★★✔∏ organization initiat≈✔$ed mainly by leading enterprises in d£σ✘omestic medicine and related fields,‍≥   serving as a bridge and link between<‍∏ the party, government, and this indλ"∑¶ustry.

Beijing Haibu Pharmaceutical φ©εTechnology Co., Ltd. (abbre₩  ¶viated as "Haibu Pharmaceutical") was ★  established in 2005 and >&is a high-tech enterprise with "c♦≥hemical drug research and development♦‍↑" as its core capability. It has aδβ ★ research center in Beiβ™jing, an API and formulation pilot veΩ&↓ rification center, and ₩✘←≈a GMP industrial production base. It §≠€mainly engages in CRO services f ¶or APIs and formulations, MAε≈₽H joint licensing, API-relat$‌ed declarations, and commercial su∑'pply of pharmaceutical φ™intermediates.It has rich experience in σ←₹>R&D transfer product ∑β∑ion, registration declaration ≤♣≠₹for various dosage fo λ<rms such as chemical raw mat•±erials drugs, oral solids, liquid prep₹♠↑ arations, sterile injecti≠€π>ons, external preparations etc. Th÷ e R&D products cover multipβ•₩le therapeutic areas↔σ including anti-tumor, anti-depress®≥αion, anti-epilepsy, anti-an ←‌xiety, cardiovascular d↑'£ iseases, digestive system diseases,→↔ respiratory system diseas ε∏es.

Haibu Pharmaceutical has been awarde♦>✘d "Top 20 Chinese Pharmaceutical ™✘← R&D Companies" for sever♣$φ™al consecutive years and recognized as ₹☆a "Specialized & Innovativ♠←&e" enterprise in Beijing; a "≠₹£€National High-tech Enterprise"; a "Beij≥™ing Science & Techno₩≤®logy Research Development Instε>itution"; and a "Beijing Yi↔£zhuang Enterprise Innovation ​≠Center", among others.